Purpose: To determine whether transrectal ultrasound-guided biopsy of the prostate is equally reliable and acceptable if performed by urology nurse practitioner or urologist. Scope: Octant biopsies were taken by each operator (consultant urologist n ¼ 2, urology specialist registrar n ¼ 1 and urology nurse practitioner n ¼ 2) from 50 consecutive unselected patients and demographics and cancer detection rate were compared between the groups. A postal survey was performed following nurse practitioner biopsy to assess patient satisfaction and acceptance of nurse practitioner biopsy. Conclusion: Transrectal ultrasound-biopsy of prostate whether performed by nurse practitioner or urologist is equally reliable if adequate training is provided. Patients are happy to undergo prostate biopsy and receive information about the diagnosis from an appropriately trained prostate cancer nurse specialist.
Introduction
Prostate cancer is the commonest cancer in men in the UK, with a incidence of 24 700 in 1999 and one in 14 men diagnosed with cancer within their lifetime. 1 The incidence of prostate cancer is increasing due to a combination of effects including more widespread detection using serum PSA assay and the increasing longevity of the UK population resulting in a greater number of men at risk. The widespread availability of PSA testing has increased the number of men requiring prostate biopsy to investigate them for prostate cancer. The use of transrectal ultrasound (TRUS) to perform systematic biopsy of the prostate 2 has become a gold standard for prostate cancer detection. The optimum number of prostate biopsies is still a matter of some debate; however, using eight biopsies seems to add significant diagnostic yield compared with sextant biopsy 3 and has been adopted in many UK centres as a standard initial biopsy strategy.
The current demand for prostate biopsy has presented a workforce problem in the UK. This problem is being progressively compounded by the impact of the European working time directive that already theoretically limits the hours worked by senior doctors and is being progressively implemented among training grade doctors. Further reductions in the availability of UK junior doctors for procedures such as TRUS and prostate biopsy has resulted from the 1993 Calman Report 4 on training, which recommended more structured training with less provision of routine services by doctors in training. As the medical workforce has come under increasing pressure to deliver high-quality services in a timely manner with limited expansion in consultant numbers, nurse practitioners have been looked to for assistance. 5 While many nurses agree that an overlap exists between the work of doctors and nurses, caution is necessary to ensure that such extra duties will contribute to quality of care for individual patients and to the expansion of the role of the nurse without exposure of patients to additional risk, or nurse practitioners to unsupported practice or litigation.
In our practice, potential roles for nurse practitioners were identified in agreement with medical staff and following consultation with the standards suggested by the United Kingdom Central Council for Nursing, Midwifery and Health Visiting (UKCC, now Nursing and Midwifery Council) 'Scope of Professional Practice' document. 6 These roles included the provision of a nurse-delivered prostate biopsy service and subsequent explanation of the outcome of prostate biopsy to the patient. Once these roles had been identified, a training programme was initiated and this included a single-day theory and anatomy teaching session, the observation of 20 cases, identification of TRUS anatomy in 30 cases with a urologist as mentor, and 50 cases of prostate biopsy with supervision by a urologist. The training period was completed by a summative assessment by an external consultant urologist who assessed the ability of the nurse practitioner on technical, academic and administrative aspects of service provision.
Following completion of the training programme, supervised biopsy period and summative assessment by two nurse specialists we audited the efficacy of cancer detection and patient satisfaction prospectively to determine if there were any clear differences between the outcome of biopsies performed by nurse practitioners or medical staff. We also studied a subgroup of patients to assess any concerns about nurse practitioners providing a biopsy and information service. Although we asked patients to report adverse events at follow-up, we did not attempt to address rates of urinary sepsis or minor complications during this study.
Patients and methods
In this prospective study first-time biopsies were taken independently by each operator from 50 consecutive unselected patients. Patients were booked directly for biopsy if adequate information was available from a GP referral letter or referred by a Urologist from the outpatient clinic. All patients booked for biopsy performed by nurse practitioner were sent a letter informing them that their biopsy was to be performed by a nurse specialist in prostate cancer and offering the option of a medical operator if preferred. Repeat biopsies for any indication and biopsies following treatment for prostate cancer was not assessed during this study. Five operators performed biopsies; two consultant urologists, one specialist registrar and two prostate cancer nurse specialists. Both of the consultants had 45 y experience with TRUS and biopsy compared with 1 year for the specialist registrar. The medical staff had gained supervised experience of prostate biopsy prior to the study and routinely performed the procedure, but had not undergone formal summative assessment. The previously described training programme was completed only by the nurse practitioners. Criteria for biopsy were abnormal digital rectal examination of the prostate gland or raised age-related PSA.
All studied patients received their first set of prostate biopsies during the study and a standard set of octant biopsies were taken. These comprised sextant biopsies with additional lateral peripheral zone biopsy of the mid-gland as described by Presti et al. 3 We have adopted octant biopsy as a standard for men undergoing their first set of prostate biopsies. All biopsies were performed under ciprofloxacin cover (500 mg BD Â 3-5 doses with the first dose taken at least 2 h prior to biopsy).
In order to ensure that the groups biopsied by different operators came from a homogeneous population, age, clinical TNM staging (UICC, 1997) and prebiopsy PSA were recorded prospectively. Evaluation of needle biopsies was performed by a designated uropathologist. We then divided the biopsy results into four groups that were classified as patients with benign conditions (biopsies contained only BPH, fibromuscular tissue, etc), prostate carcinoma (any biopsies contained any prostate carcinoma), high-grade PIN (any biopsies containing PIN but no carcinoma), or specimens containing no prostate tissue (other tissue types or tissue too fragmented for adequate diagnostic assessment). For multivariate analysis, patients were classified in a binary (cancer present/cancer absent) fashion.
Univariate analyses of data were performed using parametric (ANOVA) and nonparametric (KruskallWallis) methods as appropriate. Prebiopsy data were analysed to ensure that patients came from a homogeneous population. Further univariate analysis was performed to assess the effect of PSA, DRE, age, operator grade and operator on biopsy outcome (determined as either cancer detected or cancer absent). An unconditional logistic regression analysis (SYSAT 10, SPSS Science) was performed as described by Altman. 7 Factors associated with biopsy outcome at a significance level of r0.10 in the univariate analysis were considered for inclusion in the model. Factors associated with biopsy outcome at a significance level of o0.05 in the multivariate analysis were included in the final model.
A postal survey without reminders was performed to assess patient's satisfaction and acceptance of nurse practitioners in this extended role. The questions were administered to 87 consecutive patients including patients biopsied outside of this series. These patients underwent biopsy by one of the nurse practitioners (DH), with 72 patients (83%) returning questionnaires. A sample questionnaire is reproduced in Figure 6 (with patients replies).
Results
None of the patients contacted the Urology department to request biopsy by medical rather than nursing Biopsy outcome following trus-guided prostate biopsy A Henderson et al personnel. Demographics are summarised in Figure 1 . The only significant difference between the groups was age (ANOVA P ¼ 0.03) with the consultant group being significantly younger than the SPR group (Bonferroni post hoc analysis P ¼ 0.05) but without significant differences between the nurse group and other groups. Mean PSA was highest in the nurse biopsy group though the differences were not statistically significant (Figure 2) .
Histopathological results are summarised in Figures 3  and 4 . None of the patients underwent biopsies that did not contain prostate material. Cancer detection was equal between nurse specialist and consultant at 45% with 44% of the biopsy sets taken by the SPR containing cancer. PIN detection was slightly higher in the consultant group than in the SPR or nurse-biopsied group; however, the difference was not statistically significant. There was no statistical difference in outcome of biopsy between grade of operator (consultant/SPR/nurse Kruskal-Wallis P ¼ 0.372) or individual performing biopsy (KruskalWallis, P ¼ 0.373). Univariate analysis showed significantly (Po0.05) higher age, PSA and DRE TNM stage in patients with prostate cancer compared with patients with PIN or benign histology. Multivariate analysis of all 250 biopsies revealed that only PSA (P ¼ 0.002 odds ratio 95% CI 1.075-1.017) and DRE (P ¼ 0.007 odds ratio 95% CI 3.01-1.19) and not age, operator or operator grade were significantly associated with risk of prostate cancer detected on biopsy. Figure 5 summarises % cancer detection by PSA group (groups comprised patients with serum PSA 0-5, 5.1-10, 10.1-20 or 420 ng/ml). It is clear that even within these subgroups there was no significant relationship between operator and cancer detection rate. 
Figure 6
Questionnaire replies for patients following biopsy by nurse practitioner n ¼ 72 (83% response rate).
Biopsy outcome following trus-guided prostate biopsy A Henderson et al
Patient survey results are summarised in Figure 6 . Though 4% of patients were worried about nurse practitioners performing biopsies 96% of patients either had no preference or would prefer the nurse to perform any future biopsies. Only 11% of patients would not be happy to receive the biopsy result from a nurse practitioner.
None of our patients required readmission for complications of prostate biopsy and none reported treatment for complications of prostate biopsy at follow-up.
Discussion
Nurse practitioners were able to take octant prostate biopsies with equivalent diagnostic yield to consultant urologists. The rates of cancer detection were similar between operators even within PSA-risk group stratified patient samples. This suggests that nurse practitioners with appropriate training are achieving similar sampling of the prostate to consultant urologists and that smaller cancers (in the PSA 0-5 group) are not being missed. High rates of prostate cancer detection in all groups reflect the relatively selected patient group that was referred from the unscreened UK population (Figure 3-5) .
Our study did not address the use of a periprostatic lignocaine block, 8, 9 which is now our standard practice; however, this is a technically simple procedure, which has been adopted by our nurse practitioners. It is reassuring to note that no patients were readmitted after prostate biopsy although minor complications may not have been reported by patients during this study.
The provision of a diagnostic service by nurse practitioners including prostate biopsy and result of prostate biopsy was acceptable to the majority of patients although it is important that the patients are informed that a nurse specialist is to undertake the biopsy as a minority of patients may prefer a medical operator.
Prostate biopsy is a useful addition to the range of skills practiced by nurse practitioners. The presence of appropriately trained nurse practitioners in centres offering diagnostic services for prostate cancer not only provides increased capacity to deliver a timely diagnostic intervention, but may also increase the patient's continuity of care. In our institutions, nurses perform the first consult and biopsy in patients selected after a review of correspondence from GP to consultant urologist, or a biopsy after an initial consultation with a Urologist. It is essential that decision making regarding whom to biopsy, the long-term management of biopsy-negative patients and which definitive treatment to offer patients diagnosed with cancer remains the remit of the urologist, however, this should not prevent the urological community from utilising the valuable resource of nurse practitioners. There is also no reason why nurse practitioners with appropriate experience and teaching skills cannot pass the skills of prostate biopsy on to trainee urologists.
